Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051 · tracked via the Priya Life Science USA tracker

Sponsor

Glaukos Corporation

Phase

Not applicable

Started

2023-09-01

Last updated

2023-09-28

Condition(s) studied

Glaucoma

Investigational drug(s) / intervention(s)

iStent Infinite

iStent Infinite: iStent Infinite Trabecular Micro-Bypass System

Study summary

Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment

Eligibility

Sex

ALL

Min age

35 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Diagnosis of primary open-angle glaucoma * Phakic or pseudophakic * Age 35 years or older Exclusion Criteria: * Traumatic, uveitic, neovascular, angle-closure glaucoma or * glaucoma associated with vascular disorders * Active corneal inflammation or edema * Retinal disorders not associated with glaucoma

Primary outcome measure(s)

Mean Diurnal Intraocular Pressure (IOP) 12-Month reduction ≥ 20% from Baseline — 12 Months

Trial sites (1)

Facility	City	Region	Status
Glaukos Investigator Site	Cincinnati	Ohio	Recruiting

More Glaukos Corporation trials in the USA

Travoprost Intraocular Implant + iStent Infinite Recruiting

Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus Recruiting

A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED Recruiting

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis Recruiting

Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Recruiting

Other trials for the same condition

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone) Recruiting

Phase 2 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant Recruiting

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine) Recruiting

A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage Recruiting

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06057051 on ClinicalTrials.gov ↗ ← All trials in the USA